Company intelligence / Profile preview

FIHO

Ownership: Private
Development stage: Other

Overview

Phio Pharmaceuticals is advancing its proprietary INTASYL self-delivering siRNA platform, with clinical-stage programs focused on enhancing immune cell efficacy against tumors. The company targets cutaneous squamous cell carcinoma and melanoma, leveraging Nobel Prize-winning science in RNA interference. Recent updates indicate a pivot from discovery to development under new leadership, but detailed clinical results are not specified on their website.

Therapeutic areas: Oncology
Modalities: Small interfering RNA (siRNA)RNA therapyGene silencing technology
Industry: Biotech

Beyond the preview

Go deeper on FIHO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIHO.

Explore the full profile